Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 195 Prostatic Neoplasms, Castration-Resistant 20 Neoplasm Metastasis 20 Metastatic Castration Resistant Prostate Cancer 10 Prostate Cancer Metastatic 7 Metastatic Castration-Resistant Prostate Cancer 7 Metastatic Castration-resistant Prostate Cancer 6 Neoplasms 5 Castration-resistant Prostate Cancer 5 Breast Neoplasms 5 Pancreatic Neoplasms 4 Melanoma 4 Colorectal Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Bulbo-Spinal Atrophy, X-Linked 4 Adenocarcinoma 4 Urinary Bladder Neoplasms 3 Prostate Adenocarcinoma 3 Parkinson Disease 4, Autosomal Dominant Lewy Body 3 Carcinoma, Renal Cell 3 Carcinoma, Hepatocellular 3 Uterine Cervical Neoplasms 2 Triple Negative Breast Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Small Cell Lung Carcinoma 2 Prostatic Diseases 2 Ovarian Neoplasms 2 Non-metastatic Castration-resistant Prostate Cancer 2 Metastatic Hormone-sensitive Prostate Cancer 2 Metastatic Hormone Sensitive Prostate Cancer 2

Interventions

enzalutamide 1 darolutamide 1 apalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Non-metastatic Prostate Cancer × enzalutamide × Genitourinary × Clear all

NCT06204302 2024-04-09

ARENA

Bayer

Non-metastatic Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡